<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "\\amrndhw017\ESMLogs\icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254113_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013028715</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>2</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130122</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013028715</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex>2</patientsex>
			<resultstestsprocedures>Markers (Unknown date): Have gone up a little
Genomic profile (Unknown date): 3 overamplifications, CDK4, one of her overamplifications</resultstestsprocedures>
			<reaction>
				<primarysourcereaction>Inflammatory breast cancer, metastates on its own and markers have gone up a little</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Disease progression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Disease progression</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Inflammatory breast cancer, metastates on its own and markers have gone up a little</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Inflammatory breast cancer</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Inflammatory carcinoma of the breast</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Aromasin</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-753</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>EXEMESTANE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammatory breast cancer</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammatory breast cancer</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>AFINITOR</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a non-contactable consumer.  
A female patient of unspecified age and ethnicity started to receive exemestane (AROMASIN) and everolimus (AFINITOR) both on an unspecified date. The patient's medical history and concomitant medications were not reported. She experienced inflammatory breast cancer, metastases on its own, her markers have gone up a little and she had 3 over amplifications (CDK4), one of her over amplifications. Her genomic profile showed 3 over amplifications (CDK4 one of her over amplifications). At the time of reporting, it was unknown whether therapy with exemestane and everolimus was continuing and the outcome of the event was also unknown.

No follow-up attempts possible. No further information expected.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
